| abstract |
METHODS OF ADMINISTRATION OF ELAGOLIX. The present disclosure relates to the use of GnRH receptor antagonists for the treatment of endometriosis, uterine fibroids, polycystic ovary syndrome (PCOS) or adenomyosis. In particular, the present disclosure describes methods for treating such gynecological disorders, wherein the methods involve the administration of elagolix and may further involve the co-administration of a CYP2B6 substrate (e.g. bupropion) or a CYP2C19 substrate (e.g. , omeprazole). |